Altimmune (ALT) Operating Income: 2010-2025
Historic Operating Income for Altimmune (ALT) over the last 16 years, with Sep 2025 value amounting to -$20.9 million.
- Altimmune's Operating Income rose 15.78% to -$20.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$90.5 million, marking a year-over-year increase of 19.18%. This contributed to the annual value of -$103.2 million for FY2024, which is 7.55% down from last year.
- As of Q3 2025, Altimmune's Operating Income stood at -$20.9 million, which was up 9.00% from -$22.9 million recorded in Q2 2025.
- Altimmune's Operating Income's 5-year high stood at -$14.9 million during Q1 2021, with a 5-year trough of -$33.6 million in Q4 2023.
- For the 3-year period, Altimmune's Operating Income averaged around -$24.1 million, with its median value being -$22.9 million (2025).
- Per our database at Business Quant, Altimmune's Operating Income plummeted by 123.12% in 2021 and then grew by 26.04% in 2024.
- Over the past 5 years, Altimmune's Operating Income (Quarterly) stood at -$24.0 million in 2021, then rose by 3.71% to -$23.1 million in 2022, then crashed by 45.59% to -$33.6 million in 2023, then climbed by 26.04% to -$24.9 million in 2024, then climbed by 15.78% to -$20.9 million in 2025.
- Its last three reported values are -$20.9 million in Q3 2025, -$22.9 million for Q2 2025, and -$21.8 million during Q1 2025.